shutterstock_1426719905_piotr_swat
Piotr Swat / Shutterstock.com
25 August 2020AmericasSarah Morgan

Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute

A district judge has given India-based  Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against  Indivior.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
15 July 2019   The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.
Americas
13 August 2020   Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.

More on this story

Big Pharma
15 July 2019   The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.
Americas
13 August 2020   Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.

More on this story

Big Pharma
15 July 2019   The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.
Americas
13 August 2020   Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.